BCM
KRYS icon

BlueCrest Capital Management’s Krystal Biotech KRYS Stock Holding History

BlueCrest Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-9,280
Closed -$305K – 760
2019
Q1 		$305K Buy
+9,280
New +$219K 0.01% 698

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlueCrest Capital Management's KRYS Position: Q2 2019 in Review

BlueCrest Capital Management sold out of Krystal Biotech (KRYS) in Q2 2019, closing a stake of 9,280 shares — an estimated $305K sold.

BlueCrest Capital Management first reported a position in KRYS in Q1 2019 and held it in 1 quarter. The position peaked at $305K in Q1 2019. 76 funds tracked by Wall St. Rank hold KRYS as of Q2 2019.

  • BlueCrest Capital Management reported no remaining Krystal Biotech position as of Q2 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 9,280 Krystal Biotech shares in Q2 2019, an estimated $305K.
  • BlueCrest Capital Management first reported a position in Krystal Biotech in Q1 2019 and held it in 1 quarter.
  • BlueCrest Capital Management's Krystal Biotech position peaked at $305K in Q1 2019.
  • 76 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.